CONCORDBIO
CONCORDBIO
CONCORDBIO · NSE
₹548.2
-1.47% (-₹8.2)
Prev. close
₹556.4
Volume
1,28,839
Delivery %
57.4%
As of
20 Nov 2026
Price history
Sumeet Bagadia · Choice Equity Broking · 05 Feb 2025, 06:12 IST
“Recommends buying Concord Biotech for intraday trading at ₹2,237.25, targeting ₹2,394 with a stop loss at ₹2,159, driven by positive market sentiment and a breakout strategy.”
Entry ₹2,237.25Target ₹2,394 (+7.0%)Stop ₹2,159 (-3.5%)R:R 2.0:1Never triggered — entry didn't fill
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Recommends buying Concord Biotech in the ₹1,700–1,670 range for the near term, targeting ₹1,850 with a stop-loss at ₹1,6…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Concord Biotech Ltd | NOT TRIGGERED | ||||
| “Bullish on Concord Biotech Limited, recommending a buy above ₹1,930 and on dips to ₹1,860, with a target price of ₹2,105…” | Raja VenkatramanNeoTrader | Concord Biotech Limited | MISS | ||||
| “Bullish on CONCORDBIO, recommending to buy above ₹1930 and on dips to ₹1860, with a target price of ₹2105-2155 within 1 …” | Raja VenkatramanNeoTrader | Concord Biotech Ltd | MISS | ||||
| “Bullish on Concord Biotech with a target of ₹2610 and a stop loss at ₹2233, for traders with a short-term trading horizo…” | Aakash HindochaNuvama Professional Clients Group | Concord Biotech Ltd | MISS | ||||
| “Recommends buying Concord Biotech for intraday trading at ₹2,237.25, targeting ₹2,394 with a stop loss at ₹2,159, driven…” | Sumeet BagadiaChoice Equity Broking | Concord Biotech Ltd | MISS | ||||
“Recommends buying Concord Biotech for intraday trading at ₹2,237.25, targeting ₹2,394 with a stop loss at ₹2,159, driven by positive market sentiment and a breakout strategy.” How this call is judged A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. Entry: ₹2,237.25, as stated. Target ₹2,394, stop ₹2,159, as stated. Window: 30 days, the time frame the call states ("intraday"). The stop ₹2,159 was reached on a close before the target ₹2,394. Miss. The grader's working: R3 TRADE_SETUP: entered ₹2235.2 on 2025-02-10 (stated entry ₹2237.25, DIP_LIMIT entry, filled); stop ₹2159 breached at close ₹2131.2 on 2025-02-11. Window 30 days — rule H1: the quote says "intraday" (a one-day claim, judged over 30 days; MISS if neither level is reached). (11 Feb 2025) | |||||||
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “MarketSmith India recommends buying Concord Biotech Ltd. within the range of ₹2,210-2,245, setting a profit goal of ₹2,8…” | Marketsmith India AnalysisMarketsmith India | Concord Biotech Ltd | — |
About Concord Biotech Limited
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ankur Vaid
Headquarters
Ahmedabad
Employees
1,624
Website
concordbiotech.comExchange
View on NSE ↗Key stats
Market cap
₹13,715.18 Cr
P/E ratio (TTM)
49.1
Dividend yield
0.61%
EPS (TTM)
₹13.36
Beta (1Y · daily vs NIFTY 50)
0.99
Beta (5Y · monthly vs NIFTY 50)
1.63
Shares float
5.41 Cr
EPS · quarter ended Sept 2026
₹6.65
Financial Performance
01 · Financials
EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (revenue was nil or not reported).
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹830.63 Cr | ₹1,016.94 Cr | ₹1,200.09 Cr | ₹1,055.07 Cr | |
EBITDA | — | — | ₹380.56 Cr | ₹465.34 Cr | ₹550.78 Cr | ₹425.99 Cr |
| ₹235.00 Cr | ₹175.00 Cr | ₹240.09 Cr | ₹308.10 Cr | ₹371.64 Cr | ₹260.91 Cr | |
Diluted EPS | — | — | ₹22.95 | ₹29.13 | ₹35.65 | ₹25.17 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2024 could not be checked against the company's own annual report: this page shows ₹308.10 Cr while the annual report gives ₹304.73 Cr (1.1% apart).
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,183.00 Cr | ₹1,313.00 Cr | ₹1,514.00 Cr | ₹1,701.00 Cr | ₹2,034.00 Cr | ₹2,232.00 Cr | |
| — | — | ₹31.55 Cr | ₹9.74 Cr | ₹2.97 Cr | ₹2.32 Cr | |
Stockholders' equity | ₹1,000.00 Cr | ₹1,104.00 Cr | ₹1,290.00 Cr | ₹1,526.00 Cr | ₹1,812.00 Cr | ₹2,017.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹167.00 Cr | ₹207.00 Cr | ₹246.00 Cr | ₹265.00 Cr | ₹245.00 Cr | ₹267.00 Cr | |
Investing cash flow | — | — | ₹-157.95 Cr | ₹-154.61 Cr | ₹-159.99 Cr | ₹-142.72 Cr |
| ₹31.00 Cr | ₹-100.00 Cr | ₹-85.00 Cr | ₹-99.00 Cr | ₹-99.00 Cr | ₹-113.00 Cr | |
Capital expenditure | ₹-204.00 Cr | ₹-156.00 Cr | ₹-145.00 Cr | ₹-86.00 Cr | ₹-111.00 Cr | ₹-95.00 Cr |
End cash position | — | — | ₹3.50 Cr | ₹15.14 Cr | ₹90.45 L | ₹12.19 Cr |
Investing cash flow, Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 23–Jun 26(12Q) |
|---|---|
| Promoter | 44.08% |
| Public | 55.92% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Concord Biotech Limited | ₹12,845.82 Cr | ₹655.5 | 46.0 | 6.37 | 12.9% | 0.00 | -11.3% | -54.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Concord Control Systems Ltd (BOM:543619) (Q2 2027) Earnings Call Highlights: Revenue Nearly ...
Yahoo Finance · 11 days ago